|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-6-7
|
|
pubmed:abstractText |
This trial was designed to test the safety and efficacy of a tumor-specific genetic prodrug activation therapy targeted by use of the human erbB-2 gene promoter. The erbB-2 oncogene is overexpressed in approximately 20% of cases of breast cancer and is associated with poor prognosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2180-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10561274-Adult,
pubmed-meshheading:10561274-Aged,
pubmed-meshheading:10561274-Breast Neoplasms,
pubmed-meshheading:10561274-Cytosine Deaminase,
pubmed-meshheading:10561274-Female,
pubmed-meshheading:10561274-Fluorouracil,
pubmed-meshheading:10561274-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:10561274-Gene Therapy,
pubmed-meshheading:10561274-Genes, erbB-2,
pubmed-meshheading:10561274-Humans,
pubmed-meshheading:10561274-Middle Aged,
pubmed-meshheading:10561274-Nucleoside Deaminases,
pubmed-meshheading:10561274-Plasmids,
pubmed-meshheading:10561274-Postmenopause,
pubmed-meshheading:10561274-Prodrugs
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression.
|
|
pubmed:affiliation |
Imperial Cancer Research Fund Molecular Oncology Unit and Departments of Cancer Medicine and Histopathology, Imperial College School of Medicine, Hammersmith Campus, London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
